ENTRY       D11922            Mixture   Drug
NAME        Atoltivimab, maftivimab and odesivimab;
            atoltivimab, maftivimab, and odesivimab-ebgn;
            Inmazeb (TN)
PRODUCT     INMAZEB (Regeneron Pharmaceuticals)
COMPONENT   Atoltivimab [DR:D11468], Maftivimab [DR:D11450], odesivimab [DR:D11921]
REMARK      Product: D11922<US>
EFFICACY    Antiviral
  DISEASE   Zaire ebolavirus infection [DS:H00283]
  TYPE      Monoclonal antibody, combination
TARGET      Zaire ebolavirus glycoprotein [KO:K24534]
  PATHWAY   ko03230(K24534)  Viral genome structure
BRITE       Antimicrobials [BR:br08307]
             Antivirals
              Entry, fusion or uncoating inhibitor
               Ebolavirus glycoprotein
                D11922  Atoltivimab, maftivimab and odesivimab &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D11922
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11922
///
